307 related articles for article (PubMed ID: 29615432)
1. Adoptive Immunotherapy Using PRAME-Specific T Cells in Medulloblastoma.
Orlando D; Miele E; De Angelis B; Guercio M; Boffa I; Sinibaldi M; Po A; Caruana I; Abballe L; Carai A; Caruso S; Camera A; Moseley A; Hagedoorn RS; Heemskerk MHM; Giangaspero F; Mastronuzzi A; Ferretti E; Locatelli F; Quintarelli C
Cancer Res; 2018 Jun; 78(12):3337-3349. PubMed ID: 29615432
[TBL] [Abstract][Full Text] [Related]
2. Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma.
Donovan LK; Delaidelli A; Joseph SK; Bielamowicz K; Fousek K; Holgado BL; Manno A; Srikanthan D; Gad AZ; Van Ommeren R; Przelicki D; Richman C; Ramaswamy V; Daniels C; Pallota JG; Douglas T; Joynt ACM; Haapasalo J; Nor C; Vladoiu MC; Kuzan-Fischer CM; Garzia L; Mack SC; Varadharajan S; Baker ML; Hendrikse L; Ly M; Kharas K; Balin P; Wu X; Qin L; Huang N; Stucklin AG; Morrissy AS; Cavalli FMG; Luu B; Suarez R; De Antonellis P; Michealraj A; Rastan A; Hegde M; Komosa M; Sirbu O; Kumar SA; Abdullaev Z; Faria CC; Yip S; Hukin J; Tabori U; Hawkins C; Aldape K; Daugaard M; Maris JM; Sorensen PH; Ahmed N; Taylor MD
Nat Med; 2020 May; 26(5):720-731. PubMed ID: 32341580
[TBL] [Abstract][Full Text] [Related]
3. Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.
Tsuji T; Yoneda A; Matsuzaki J; Miliotto A; Ryan C; Koya RC; Odunsi K
Cancer Immunol Res; 2018 May; 6(5):594-604. PubMed ID: 29588318
[TBL] [Abstract][Full Text] [Related]
4. Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma.
Budde LE; Berger C; Lin Y; Wang J; Lin X; Frayo SE; Brouns SA; Spencer DM; Till BG; Jensen MC; Riddell SR; Press OW
PLoS One; 2013; 8(12):e82742. PubMed ID: 24358223
[TBL] [Abstract][Full Text] [Related]
5. PRAME gene expression profile in medulloblastoma.
Vulcani-Freitas TM; Saba-Silva N; Cappellano A; Cavalheiro S; Toledo SR
Arq Neuropsiquiatr; 2011 Feb; 69(1):9-12. PubMed ID: 21359415
[TBL] [Abstract][Full Text] [Related]
6. Massive clonal expansion of medulloblastoma-specific T cells during adoptive cellular therapy.
Flores C; Wildes T; Dean BD; Moore G; Drake J; Abraham R; Gil J; Yegorov O; Yang C; Dean J; Moneypenny C; Shin D; Pham C; Krauser J; King J; Grant G; Driscoll T; Kurtzberg J; McLendon R; Gururangan S; Mitchell D
Sci Adv; 2019 Nov; 5(11):eaav9879. PubMed ID: 31807694
[TBL] [Abstract][Full Text] [Related]
7. Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine.
Yan M; Himoudi N; Basu BP; Wallace R; Poon E; Adams S; Hasan F; Xue SA; Wilson N; Dalgleish A; Williams O; Anderson J
Cancer Immunol Immunother; 2011 Sep; 60(9):1243-55. PubMed ID: 21553146
[TBL] [Abstract][Full Text] [Related]
8. An analysis of T-cell-receptor variable-region genes in tumor-infiltrating lymphocytes within malignant tumors.
Nitta T; Sato K; Okumura K; Steinman L
Int J Cancer; 1991 Oct; 49(4):545-50. PubMed ID: 1655662
[TBL] [Abstract][Full Text] [Related]
9. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia.
Kirkey DC; Loeb AM; Castro S; McKay CN; Perkins L; Pardo L; Leonti AR; Tang TT; Loken MR; Brodersen LE; Loeb KR; Scheinberg DA; Le Q; Meshinchi S
Blood Adv; 2023 Apr; 7(7):1178-1189. PubMed ID: 35984639
[TBL] [Abstract][Full Text] [Related]
11. IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System.
Puig-Saus C; Parisi G; Garcia-Diaz A; Krystofinski PE; Sandoval S; Zhang R; Champhekar AS; McCabe J; Cheung-Lau GC; Truong NA; Vega-Crespo A; Komenan MDS; Pang J; Macabali MH; Saco JD; Goodwin JL; Bolon B; Seet CS; Montel-Hagen A; Crooks GM; Hollis RP; Campo-Fernandez B; Bischof D; Cornetta K; Gschweng EH; Adelson C; Nguyen A; Yang L; Witte ON; Baltimore D; Comin-Anduix B; Kohn DB; Wang X; Cabrera P; Kaplan-Lefko PJ; Berent-Maoz B; Ribas A
Clin Cancer Res; 2019 Feb; 25(3):1000-1011. PubMed ID: 30409823
[TBL] [Abstract][Full Text] [Related]
12. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.
Chang AY; Dao T; Gejman RS; Jarvis CA; Scott A; Dubrovsky L; Mathias MD; Korontsvit T; Zakhaleva V; Curcio M; Hendrickson RC; Liu C; Scheinberg DA
J Clin Invest; 2017 Jun; 127(7):2705-2718. PubMed ID: 28628042
[TBL] [Abstract][Full Text] [Related]
13. Multi-cistronic vector encoding optimized safety switch for adoptive therapy with T-cell receptor-modified T cells.
van Loenen MM; de Boer R; Hagedoorn RS; Jankipersadsing V; Amir AL; Falkenburg JH; Heemskerk MH
Gene Ther; 2013 Aug; 20(8):861-7. PubMed ID: 23364317
[TBL] [Abstract][Full Text] [Related]
14. Regression of experimental medulloblastoma following transfer of HER2-specific T cells.
Ahmed N; Ratnayake M; Savoldo B; Perlaky L; Dotti G; Wels WS; Bhattacharjee MB; Gilbertson RJ; Shine HD; Weiss HL; Rooney CM; Heslop HE; Gottschalk S
Cancer Res; 2007 Jun; 67(12):5957-64. PubMed ID: 17575166
[TBL] [Abstract][Full Text] [Related]
15. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.
Chen L; Qiao D; Wang J; Tian G; Wang M
Immunol Lett; 2019 Dec; 216():51-62. PubMed ID: 31597088
[TBL] [Abstract][Full Text] [Related]
16. Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells.
Stastny MJ; Brown CE; Ruel C; Jensen MC
J Pediatr Hematol Oncol; 2007 Oct; 29(10):669-77. PubMed ID: 17921847
[TBL] [Abstract][Full Text] [Related]
17. Avidity characterization of genetically engineered T-cells with novel and established approaches.
Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
[TBL] [Abstract][Full Text] [Related]
18. Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy.
Blaeschke F; Paul MC; Schuhmann MU; Rabsteyn A; Schroeder C; Casadei N; Matthes J; Mohr C; Lotfi R; Wagner B; Kaeuferle T; Feucht J; Willier S; Handgretinger R; StevanoviĆ S; Lang P; Feuchtinger T
Cytotherapy; 2019 Sep; 21(9):973-986. PubMed ID: 31351799
[TBL] [Abstract][Full Text] [Related]
19. Adoptive T-cell therapy for cancer: The era of engineered T cells.
Bonini C; Mondino A
Eur J Immunol; 2015 Sep; 45(9):2457-69. PubMed ID: 26202766
[TBL] [Abstract][Full Text] [Related]
20. PRAME peptide-specific CD8
Matko S; Manderla J; Bonsack M; Schmitz M; Bornhauser M; Tonn T; Odendahl M
Eur J Immunol; 2018 Aug; 48(8):1400-1411. PubMed ID: 29738081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
